8-KLeadership ChangesExhibits & Filings

PFIZER INC 8-K Report, Executive Changes (Jun 27, 2019)

Filed June 27, 2019For Securities:PFE

Summary

Pfizer Inc. announced on June 27, 2019, a significant addition to its Board of Directors with the election of Dr. Scott Gottlieb. Dr. Gottlieb's appointment is effective immediately and includes his assignment to two key board committees: the Regulatory and Compliance Committee and the Science and Technology Committee. This move signals Pfizer's commitment to strengthening its expertise in critical areas of drug development and market access. Dr. Gottlieb, who recently concluded his tenure as Commissioner of the U.S. Food and Drug Administration (FDA), brings a wealth of experience in regulatory affairs and public health policy. His insights are expected to be invaluable as Pfizer navigates the complex regulatory landscape and pursues advancements in its scientific and technological endeavors. Dr. Gottlieb will receive compensation consistent with Pfizer's standard policies for non-employee directors and is protected by a standard indemnification agreement.

Key Highlights

  • 1Dr. Scott Gottlieb elected to Pfizer's Board of Directors, effective immediately.
  • 2Dr. Gottlieb appointed to the Regulatory and Compliance Committee.
  • 3Dr. Gottlieb appointed to the Science and Technology Committee.
  • 4Dr. Gottlieb's extensive experience as former FDA Commissioner is a key asset.
  • 5His appointment is intended to enhance expertise in regulatory and scientific matters.
  • 6Dr. Gottlieb will be compensated according to the company's standard director arrangements.
  • 7He will receive an indemnification agreement, a standard practice for board members.

Frequently Asked Questions

Dr. Scott Gottlieb is a highly regarded figure in the healthcare and pharmaceutical industry, having served as the Commissioner of the U.S. Food and Drug Administration (FDA) until April 2019. His appointment to Pfizer's Board of Directors is significant because it brings deep expertise in regulatory affairs, public health policy, and drug development oversight, which are crucial for a global pharmaceutical company like Pfizer.

Dr. Gottlieb has been appointed to two important committees of Pfizer's Board of Directors: the Regulatory and Compliance Committee and the Science and Technology Committee. These roles will allow him to directly contribute to Pfizer's strategies concerning regulatory approvals, compliance, and scientific innovation.

Dr. Gottlieb will receive compensation in line with Pfizer's standard arrangements for its non-employee directors. This typically includes a combination of cash retainers and stock awards, reflecting his contributions as an independent board member. He will also be provided with an indemnification agreement, which is a common protection for directors.

While the 8-K filing does not explicitly state immediate strategic shifts, Dr. Gottlieb's appointment, particularly his roles on the Regulatory and Compliance and Science and Technology committees, suggests a continued focus on navigating complex regulatory environments and driving scientific innovation. His background is expected to provide valuable guidance as Pfizer continues to develop and bring new medicines to market.